Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, And Nipah viruses by using a novel high-throughput screening assay

Journal of Virology

Volumn 88, Issue 8, 2014, Pages 4353-4365

  Elshabrawy, Hatem A ^a,d,e   Fan, Jilao ^a   Haddad, Christine S ^a   Ratia, Kiira ^b   Broder, Christopher C ^c   Caffrey, Michael ^a   Prabhakar, Bellur S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d CAIRO UNIVERSITY   (Egypt)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CATHEPSIN L; GLYCOPROTEIN; HYBRID PROTEIN; NEUROPEPTIDE Y;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EBOLA VIRUS; ENZYME INHIBITION; HENDRA VIRUS; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; INHIBITION KINETICS; NIPAH VIRUS; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN CLEAVAGE; SARS CORONAVIRUS; STRUCTURE ANALYSIS; VIRUS ENTRY;

ANTIVIRAL AGENTS; CATHEPSIN L; DRUG EVALUATION, PRECLINICAL; EBOLAVIRUS; HENDRA VIRUS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NIPAH VIRUS; SARS VIRUS; SMALL MOLECULE LIBRARIES; VIRAL ENVELOPE PROTEINS; VIRUS DISEASES;

EID: 84896904424     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03050-13     Document Type: Article

References (56)

1. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, Wong SS, Leung SY, Chan KH, Yuen KY. 2005. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. U. S. A. 102:14040-14045. http://dx.doi.org/10.1073/pnas.0506735102.
2. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, Zhang J, McEachern J, Field H, Daszak P, Eaton BT, Zhang S, Wang LF. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science 310:676-679. http://dx.doi.org/10.1126/science.1118391.
3. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Delicat A, Paweska JT, Gonzalez JP, Swanepoel R. 2005. Fruit bats as reservoirs of Ebola virus. Nature 438:575-576. http://dx.doi.org/10.1038/438575a.
4. Field HE, Mackenzie JS, Daszak P. 2007. Henipaviruses: emerging paramyxoviruses associated with fruit bats. Curr. Top. Microbiol. Immunol. 315:133-159. http://dx.doi.org/10.1007/978-3-540-70962-6_7.
5. Halpin K, Hyatt AD, Fogarty R, Middleton D, Bingham J, Epstein JH, Rahman SA, Hughes T, Smith C, Field HE, Daszak P, Henipavirus Ecology Research G. 2011. Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am. J. Trop. Med. Hyg. 85:946-951. http://dx.doi.org/10.4269/ajtmh.2011.10-0567.
6. Middleton DJ, Weingartl HM. 2012. Henipaviruses in their natural animal hosts. Curr. Top. Microbiol. Immunol. 359:105-121. http://dx.doi.org/10.1007/82_2012_210.
7. Peiris JS, Guan Y, Yuen KY. 2004. Severe acute respiratory syndrome. Nat. Med. 10:S88-S97. http://dx.doi.org/10.1038/nm1143.
8. Seah SK. 1978. Lassa, Marburg and Ebola: newly described African fevers. Can. Med. Assoc. J. 118:347-348.
9. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Ksiazek TG, Zaki SR, Paul G, Lam SK, Tan CT. 1999. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354:1257-1259. http://dx.doi.org/10.1016/S0140-6736(99)04299-3.
10. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh W, Goldsmith CS, Gubler DJ, Roehrig JT, Eaton B, Gould AR, Olson J, Field H, Daniels P, Ling AE, Peters CJ, Anderson LJ, Mahy BW. 2000. Nipah virus: a recently emergent deadly paramyxovirus. Science 288:1432-1435. http://dx.doi.org/10.1126/science.288.5470.1432.
11. Kielian M, Jungerwirth S. 1990. Mechanisms of enveloped virus entry into cells. Mol. Biol. Med. 7:17-31.
12. Pager CT, Dutch RE. 2005. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J. Virol. 79:12714-12720. http://dx.doi.org/10.1128/JVI.79.20.12714-12720.2005.
13. Pager CT, Craft WW, Jr, Patch J, Dutch RE. 2006. A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L. Virology 346:251-257. http://dx.doi.org/10.1016/j.virol.2006.01.007.
14. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. 2005. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U. S. A. 102:11876-11881. http://dx.doi.org/10.1073/pnas.0505577102.
15. Kaletsky RL, Simmons G, Bates P. 2007. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J. Virol. 81:13378-13384. http://dx.doi.org/10.1128/JVI.01170-07.
16. Qian Z, Dominguez SR, Holmes KV. 2013. Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS One 8:e76469. http://dx.doi.org/10.1371/journal.pone.0076469.
17. Lisco A, Vanpouille C, Tchesnokov EP, Grivel JC, Biancotto A, Brichacek B, Elliott J, Fromentin E, Shattock R, Anton P, Gorelick R, Balzarini J, McGuigan C, Derudas M, Götte M, Schinazi RF, Margolis L. 2008. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 4:260-270. http://dx.doi.org/10.1016/j.chom.2008.07.008.
18. McMahon MA, Siliciano JD, Lai J, Liu JO, Stivers JT, Siliciano RF, Kohli RM. 2008. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J. Biol. Chem. 283:31289-31293. http://dx.doi.org/10.1074/jbc. C800188200.
19. Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, Fife KH, Delany-Moretlwe S, de Bruyn G, Bukusi EA, Karita E, Kapiga S, Corey L, Wald A. 2013. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J. Infect. Dis. 208:1366-1374. http://dx.doi.org/10.1093/infdis/jit333.
20. Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD. 2008. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob. Agents Chemother. 52:329-332. http://dx.doi.org/10.1128/AAC.01004-07.
21. Menéndez-Arias L, Tozsér J. 2008. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol. Sci. 29:42-49. http://dx.doi.org/10.1016/j.tips.2007.10.013.
22. Reyskens KM, Essop MF. 2014. HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system. Biochim. Biophys. Acta 1842: 256-268. http://dx.doi.org/10.1016/j.bbadis.2013.11.019.
23. Vanderlinden E, Naesens L. 25 June 2013. Emerging antiviral strategies to interfere with influenza virus entry. Med. Res. Rev. http://dx.doi.org/10.1002/med.21289.
24. Govorkova EA, Baranovich T, Seiler P, Armstrong J, Burnham A, Guan Y, Peiris M, Webby RJ, Webster RG. 2013. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Res. 98:297-304. http://dx.doi.org/10.1016/j.antiviral.2013.02.013.
25. Von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423. http://dx.doi.org/10.1038/363418a0.
26. Woods JM, Bethell RC, Coates JA, Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcott SM. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37: 1473-1479. http://dx.doi.org/10.1128/AAC.37.7.1473.
27. Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H. 2013. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan. Antiviral Res. 99:261-269. http://dx.doi.org/10.1016/j.antiviral.2013.06.003.
28. Bosch BJ, Bartelink W, Rottier PJ. 2008. Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J. Virol. 82:8887-8890. http://dx.doi.org/10.1128/JVI.00415-08.
29. Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ. 2010. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J. Virol. 84:2972-2982. http://dx.doi.org/10.1128/JVI.02151-09.
30. Michalski WP, Crameri G, Wang L, Shiell BJ, Eaton B. 2000. The cleavage activation and sites of glycosylation in the fusion protein of Hendra virus. Virus Res. 69:83-93. http://dx.doi.org/10.1016/S0168-1702 (00)00169-6.
31. Moll M, Diederich S, Klenk HD, Czub M, Maisner A. 2004. Ubiquitous activation of the Nipah virus fusion protein does not require a basic amino acid at the cleavage site. J. Virol. 78:9705-9712. http://dx.doi.org/10.1128/JVI.78.18.9705-9712.2004.
32. Funkelstein L, ToneffT, Hwang SR, Reinheckel T, Peters C, Hook V. 2008. Cathepsin L participates in the production of neuropeptide Y in secretory vesicles, demonstrated by protease gene knockout and expression. J. Neurochem. 106:384-391. http://dx.doi.org/10.1111/j.1471-4159.2008.05408.x.
33. Funkelstein L, Beinfeld M, Minokadeh A, Zadina J, Hook V. 2010. Unique biological function of cathepsin L in secretory vesicles for biosynthesis of neuropeptides. Neuropeptides 44:457-466. http://dx.doi.org/10.1016/j.npep.2010.08.003.
34. Tiffen JC, Bailey CG, Ng C, Rasko JE, Holst J. 2010. Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol. Cancer 9:299. http://dx.doi.org/10.1186/1476-4598-9-299.
35. Coughlin M, Lou G, Martinez O, Masterman SK, Olsen OA, Moksa AA, Farzan M, Babcook JS, Prabhakar BS. 2007. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 361:93-102. http://dx.doi.org/10.1016/j.virol.2006.09.029.
36. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. 2012. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J. Virol. 86:6537-6545. http://dx.doi.org/10.1128/JVI.00094-12.
37. Gnirss K, Kühl A, Karsten C, Glowacka I, Bertram S, Kaup F, Hofmann H, Pöhlmann S. 2012. Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression. Virology 424:3-10. http://dx.doi.org/10.1016/j.virol.2011.11.031.
38. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. 2006. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80:4174-4178. http://dx.doi.org/10.1128/JVI.80.8.4174-4178.2006.
39. Hatesuer B, Bertram S, Mehnert N, Bahgat MM, Nelson PS, Pöhlman S, Schughart K. 2013. TMPRSS2 is essential for influenza H1N1 virus pathogenesis in mice. PLoS Pathog. 9:e1003774. http://dx.doi.org/10.1371/journal.ppat.1003774.
40. Peitsch C, Klenk HD, Garten W, Böttcher-Friebertshäuser E. 2014. Activation of influenza A viruses by host proteases from swine airway epithelium. J. Virol. 88:282-291. http://dx.doi.org/10.1128/JVI.01635-13.
41. Shirato K, Kawase M, Matsuyama S. 2013. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 87:12552-12561. http://dx.doi.org/10.1128/JVI.01890-13.
42. Abe M, Tahara M, Sakai K, Yamaguchi H, Kanou K, Shirato K, Kawase M, Noda M, Kimura H, Matsuyama S, Fukuhara H, Mizuta K, Maenaka K, Ami Y, Esumi M, Kato A, Takeda M. 2013. TMPRSS2 is an activating protease for respiratory parainfluenza viruses. J. Virol. 87:11930-11935. http://dx.doi.org/10.1128/JVI.01490-13.
43. Bertram S, Dijkman R, Habjan M, Heurich A, Gierer S, Glowacka I, Welsch K, Winkler M, Schneider H, Hofmann-Winkler H, Thiel V, Pöhlmann S. 2013. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J. Virol. 87:6150-6160. http://dx.doi.org/10.1128/JVI.03372-12.
44. Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. 2011. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J. Virol. 85:873-882. http://dx.doi.org/10.1128/JVI.02062-10.
45. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. 2010. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 84:12658-12664. http://dx.doi.org/10.1128/JVI.01542-10.
46. Selvey L, Sheridan J. 1995. Outbreak of severe respiratory disease in humans and horses due to a previously unrecognized paramyxovirus. J. Travel Med. 2:275. http://dx.doi.org/10.1111/j.1708-8305.1995.tb00679.x.
47. Selvey LA, Wells RM, McCormack JG, Ansford AJ, Murray K, Rogers RJ, Lavercombe PS, Selleck P, Sheridan JW. 1995. Infection of humans and horses by a newly described morbillivirus. Med. J. Aust. 162:642-645.
48. Elshabrawy HA, Coughlin MM, Baker SC, Prabhakar BS. 2012. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One 7:e50366. http://dx.doi.org/10.1371/journal.pone.0050366.
49. Adedeji AO, Severson W, Jonsson C, Singh K, Weiss SR, Sarafianos SG. 2013. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J. Virol. 87:8017-8028. http://dx.doi.org/10.1128/JVI.00998-13.
50. Gagnon H, Beauchemin S, Kwiatkowska A, Couture F, D'Anjou F, Levesque C, Dufour F, Desbiens AR, Vaillancourt R, Bernard S, Desjardins R, Malouin F, Dory YL, Day R. 10 December 2013. Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin. J. Med. Chem. http://dx.doi.org/10.1021/jm400633d.
51. Yu X, Sainz B, Jr, Petukhov PA, Uprichard SL. 2012. Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob. Agents Chemother. 56:6109-6120. http://dx.doi.org/10.1128/AAC.01413-12.
52. Ghosh AK, Takayama J, Rao KV, Ratia K, Chaudhuri R, Mulhearn DC, Lee H, Nichols DB, Baliji S, Baker SC, Johnson ME, Mesecar AD. 2010. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation. J. Med. Chem. 53:4968-4979. http://dx.doi.org/10.1021/jm1004489.
53. Shah PP, Wang T, Kaletsky RL, Myers MC, Purvis JE, Jing H, Huryn DM, Greenbaum DC, Smith AB, III, Bates P, Diamond SL. 2010. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol. Pharmacol. 78:319-324. http://dx.doi.org/10.1124/mol.110.064261.
54. Brinker A, Weber E, Stoll D, Voigt J, Muller A, Sewald N, Jung G, Wiesmuller KH, Bohley P. 2000. Highly potent inhibitors of human cathepsin L identified by screening combinatorial pentapeptide amide collections. Eur. J. Biochem. 267:5085-5092. http://dx.doi.org/10.1046/j.1432-1327.2000.01570.x.
55. Glowacka I, Bertram S, Muller MA, Allen P, Soilleux E, Pfefferle S, Steffen I, Tsegaye TS, He Y, Gnirss K, Niemeyer D, Schneider H, Drosten C, Pohlmann S. 2011. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 85:4122-4134. http://dx.doi.org/10.1128/JVI.02232-10.
56. Bertram S, Heurich A, Lavender H, Gierer S, Danisch S, Perin P, Lucas JM, Nelson PS, Pohlmann S, Soilleux EJ. 2012. Influenza and SARScoronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS One 7:e35876. http://dx.doi.org/10.1371/journal.pone.0035876.